ARKG Owns The Innovation Layer Enabling The Merck/Moderna First Positive Cancer Vaccine Readout

By Ovid Amadi, PhD

Multiomics Portfolio Manager and Director of Research

Ovid leads ARK’s Multiomics research team, overseeing genomics, biotechnology, and life sciences investment research.

What the INTerpath-001 result and the Tempus acquisition of Personalis mean for the ARK Genomic Revolution ETF (ARKG)

Key Takeaways

• The result: On August 19, 2026, Merck and Moderna reported the first positive Phase 3 readout for an individualized neoantigen therapy and for any messenger RNA (mRNA)-based cancer therapy.¹
• The point most coverage missed: While media headlines focused on the two large, data-reporting pharmaceutical companies, the most important, enabling technologies—tumor sequencing, artificial intelligence (AI)-driven neoantigen selection, and oligonucleotide synthesis—received little-to-no attention. ARKG owns the companies at that layer of innovation.
• The clearest expression: Personalis, the sequencing partner on the clinical program, is being acquired by Tempus, a top holding in ARKG. Tempus has been selected as the commercial partner. Tempus shares rose ~24% on the day of the readout.
• The fund: ARKG owns the innovation layer behind the Merck/Moderna readout, which, in our view, marks the beginning of the personalized-oncology opportunity, not its culmination.

What Merck and Moderna Reported

On August 19, 2026, Merck and Moderna reported positive topline results from the Phase 3 INTerpath-001 trial. The study tested intismeran autogene, an individualized neoantigen therapy often described as a “personalized cancer vaccine,” given together with Merck’s Keytruda in patients whose high-risk melanoma had been surgically removed. Unlike a conventional vaccine, each dose is manufactured from the patient’s own tumor, encoding dozens of tumor-specific targets that train the immune system to recognize and attack any cancer left behind. The trial met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival, with results the companies described as statistically significant and clinically meaningful.² 

The breakthrough’s significance extends well beyond a single drug. It is the first positive Phase 3 readout for an individualized neoantigen therapy, in our view, and the first for any messenger RNA (mRNA)-based cancer therapy—a long-awaited proof of principle for the personalized approach to oncology.  The data remain topline: overall-survival results are still immature and longer follow-up will be required. Even so, the readout reframed how investors value the companies that supply the underlying workflow, the sequencing, synthesis and artificial intelligence (AI)-driven analysis upon which personalized therapies depend, sparking a broad rally across mRNA and genomic-medicine names. Those events set the context for the questions addressed below.

1. The Trial as a Milestone, and How We Are Thinking About Positioning

We view the INTerpath-001 result as a platform-validation event for personalized oncology, not a single-company story. What matters to us is the proof of principle for the entire personalized-medicine stack, which we have long underwritten: turning a patient’s tumor into a bespoke therapy depends on sequencing, AI-driven target selection, and oligonucleotide synthesis, precisely the capabilities represented across these names. Framed differently, we do not read this as a large-pharma story so much as an innovation-enabler story: the breakthrough was made possible by the sequencing, synthesis, and AI layer delivered by companies like Tempus, and it is that enabling innovation—much of it held across the ARK Genomic Revolution ETF (ARKG)—that we believe stands to capture durable value as the personalized-oncology approach scales.

ARK manages ARKG to a five-year thesis rather than to a single session’s price action, and we concentrate toward our highest-conviction names, using both strength and weakness. We also are quite precise about read-through, because all associated names do not benefit equally:

• The most direct beneficiaries are Personalis (PSNL) and Tempus (TEM), by way of their partnerships with Moderna and Merck to sequence patients’ tumors to identify neoantigens as part of the personalized cancer vaccine clinical development and commercial production, respectively. 
• Beyond TEM and PSNL, the next bucket is oligonucleotide synthesis, where Twist Bioscience (TWST) has described AI-enabled drug discovery for nucleic acid therapeutics as its next frontier of growth—an opportunity that Twist itself sizes at a potential $1 billion serviceable addressable market by 2030—given that synthesis is the manufacturing layer every individualized neoantigen therapy consumes. 
• Natera (NTRA) is, in our view, the most underappreciated name in this group: The company is developing its own personalized cancer vaccine program. That program gets little attention from the market, and it builds directly on the tumor-informed sequencing capability behind Natera's leadership in measurable residual disease (MRD)—the same capability the INTerpath-001 result just validated. 
• Arcturus Therapeutics (ARCT) develops RNA-based medicines, including vaccines, so it may benefit from the same validation of the modality.
• Last are the general tools providers 10x Genomics (TXG), Illumina (ILMN), Pacific Biosciences (PACB) and other oncology diagnostics names like Guardant Health (GH), Veracyte (VCYT) and Freenome (FRNM), which may benefit from continued interest in—and demonstrated utility of—generating sequencing data and applying it to precision oncology. 
• The gene-editing names Intellia (NTLA) and Beam Therapeutics (BEAM) participated in a broad genomic-medicine rally, but this specific dataset is not a direct clinical read-through for editing; that is a distinct modality riding the same secular curve of collapsing sequencing costs and AI-enabled biology.

In short, the readout strengthens rather than resets ARK’s thesis, and our positioning follows conviction on a name-by-name basis.

2. ARK Genomic Revolution ETF Strategy Response

A single positive readout does not drive a wholesale sector reweighting in our strategies. We express a view at the single-name level, and our approach into a thesis-affirming catalyst is to concentrate toward our highest-conviction ideas. Tempus remains a top holding across the platform and we have been accumulating it over the past year as the clearest expression of the convergence of AI and genomics in healthcare.⁴ The INTerpath-001 result affirms positioning we already held rather than prompting a repositioning of the sleeve, and our conviction in the multiomics-plus-AI theme is intact.

3. The Tempus Acquisition of Personalis (PSNL)

In our view, Tempus is vertically integrating into its platform the final piece of the cancer-care continuum. Announced on July 20, 2026, one month before the readout, Tempus will pay $16.25 per share—a total enterprise value of ~$1.7 billion, or ~$1.5 billion net of its existing ~12.5% stake—in a primarily all-stock transaction, with an option for up to 50% cash, targeted to close in late 2026 or early 2027, with Merck, an ~13% holder, voting in favor.⁵

We find this acquisition important because Personalis is Merck's and Moderna’s clinical sequencing partner on intismeran autogene, profiling patients’ tumors to identify the neoantigens from which each individualized dose is built. That program relationship—not MRD alone—is also a strategic asset Tempus is acquiring.

The deal also fits ARK’s core thesis that the binding constraint in oncology is data integration, not science: it brings Personalis’ tumor-informed MRD technology together with Tempus’ commercial scale, multimodal data, and AI platform, extending its reach from diagnosis and treatment selection through recurrence and monitoring in what the companies size as a ~$20 billion market.⁶ MRD monitoring is a recurring, longitudinal test that feeds the Tempus data “flywheel,” and Personalis reported NeXT Personal clinical volume growth of ~199% year-over-year and ~33% quarter-over-quarter in the second quarter of 2026.⁷ 

Most compelling for us is the connection to the readout. Personalized cancer vaccines require tumor-informed sequencing to identify neoantigens up front and sensitive MRD testing to monitor response. Personalis, and eventually Tempus, supply that sequencing inside the Merck and Moderna program itself, so the INTerpath-001 validation accrues directly to Tempus. We also note other, near-term considerations: the all-stock structure carries dilution, customary deal-completion, and regulatory risk until close, and the initial market reaction was cautious, with Personalis trading down as much as 15% intraday on the announcement and Needham downgrading it to Hold—in part because of the all-stock terms. Consistent with ARK’s long-duration horizon, we believe the platform logic outweighs the near-term structural noise.

Conclusion: Positioned for the Moment, by Design

ARK Genomic Revolution ETF: Annualized Performance

Source: ARK Investment Management LLC. 2026. Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor’s shares when redeemed may be worth more or less than the original cost. Returns for less than one year are not annualized. Net asset value (“NAV”) returns are based on the dollar value of a single share of the ETF, calculated using the value of the underlying assets of the ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the Cboe BZX Exchange, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times. Total Return reflects the reinvestment of distributions on ex-date for NAV returns and payment date for Market Price returns. The market price of the ETF's shares may differ significantly from their NAV during periods of market volatility.

The market’s reaction underscored the importance and distinctiveness of the ARK Genomic Revolution strategy’s design: On the day of the readout, ARKG’s move was not a fortunate brush with a headline; it was the payoff of a multi-year thesis. ARK underwrote the convergence of artificial intelligence and genomics long before it was consensus thinking, and ARKG owns the sequencing, synthesis, and AI-enabled diagnostics layer deliberately, because we understand that any personalized-oncology breakthrough must run through it. As a result, we concentrated toward our highest-conviction names, such as Tempus. When a milestone of this kind arrives, that positioning is expressed in the portfolio. Now, investors have seen that dynamic firsthand. In effect, the move was enabled by the innovation that exemplifies ARKG’s portfolio—holdings like Tempus that supply the workflow behind the readout. Notably, that enabling layer is not the work of the large-pharma sponsors whose names dominated media headlines that cheered the Merck/Moderna readout. And we believe the world in is in the early innings of the personalized-oncology opportunity. 

Single-session moves can cut both ways, to be sure, and we do not manage to them. But the direction of travel matters most to us. The cost of reading and writing DNA continues to fall, artificial intelligence is compounding the value of the resulting data, and clinical proof points such as INTerpath-001 convert that long-run thesis into realized outcomes. We believe ARKG sits at the center of that shift, and days like this are a reminder of why.

You can learn more about the ARK Genomic Revolution ETF on our website. 

Important Information

Investors should carefully consider the investment objectives and risks as well as charges and expenses of an ARK Fund before investing. This and other information are contained in the ARK ETFs’ prospectuses and summary prospectuses, which may be obtained by visiting www.ark-funds.com. The prospectus and summary prospectus should be read carefully before investing.

An investment in an ARK Fund is subject to risks and you can lose money on your investment in an ARK Fund. There can be no assurance that the ARK Funds will achieve their investment objectives. The ARK Funds’ portfolios are more volatile than broad market averages. The ARK Funds also have specific risks, which are described below. More detailed information regarding these risks can be found in the ARK Funds’ prospectuses.

The principal risks of investing in ARKG: Equity Securities Risk. The value of the equity securities the Fund holds may fall due to general market and economic conditions. Foreign Securities Risk. Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities. Health Care Sector Risk. The health care sector may be adversely affected by government regulations and government health care programs, restrictions on government reimbursements for medical expenses, increases or decreases in the cost of medical products and services and product liability claims, among other factors. Many health care companies are heavily dependent on patent protection and intellectual property rights and the expiration of a patent may adversely affect their profitability. Biotechnology Company Risk. A biotechnology company’s valuation can often be based largely on the potential or actual performance of a limited number of products and can accordingly be greatly affected if one of its products proves, among other things, unsafe, ineffective or unprofitable. Biotechnology companies are subject to regulation by, and the restrictions of, the U.S. Food and Drug Administration, the U.S. Environmental Protection Agency, state and local governments, and foreign regulatory authorities. Pharmaceutical Company Risk. Companies in the pharmaceutical industry can be significantly affected by, among other things, government approval of products and services, government regulation and reimbursement rates, product liability claims, patent expirations and protection and intense competition. Disruptive Innovation Risk. Companies that ARK believes are capitalizing on disruptive innovation and developing technologies to displace older technologies or create new markets may not in fact do so. Companies that initially develop a novel technology may not be able to capitalize on the technology. Companies that develop disruptive technologies may face political or legal attacks from competitors, industry groups or local and national governments. These companies may also be exposed to risks applicable to sectors other than the disruptive innovation theme for which they are chosen, and the securities issued by these companies may underperform the securities of other companies that are primarily focused on a particular theme. Detailed information regarding the specific risks of ARKG can be found in the ETF’s prospectus. Additional risks of investing in ARKG include Foreign Securities Risk, Information Technology Sector Risk, equity, market, management and non-diversification risks, as well as fluctuations in market value and NAV. 

Additional risks of investing in ARK ETFs include market, management and non-diversification risks, as well as fluctuations in market value NAV. ETF shares may only be redeemed directly with the ETF at NAV by Authorized Participants, in very large creation units. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.

To view the top ten holdings for ARKG click here.

ARK Investment Management LLC is the investment adviser to the ARK Funds.

Foreside Fund Services, LLC, distributor.